These Form 3 filings confirm insider ownership ahead of an expected IPO. The large insider stakes (CEO ~4.6M shares, CMO ~642K shares, director Stampacchia ~3.6M shares via funds) indicate significant alignment with shareholders. Monitor the IPO prospectus for pricing and lock-up details.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $28.50entry
- T+1 · 15h ago +5.40%α +7.32% · $30.04
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Four Form 3 filings were filed on November 12, 2026, by insiders of Windward Bio Group AG (WWB), a pre-IPO biotech company. The filings disclose initial beneficial ownership for CEO Luca Santarelli (4,578,110 common shares and options for 163,854 shares), CMO Omar Khwaja (642,136 common shares and options for 318,830 shares), director Otello Stampacchia (indirect holdings via Omega funds totaling 3,590,530 common shares on an as-converted basis), and director Sandip Kapadia (no securities reported). These filings are routine initial ownership disclosures required upon becoming Section 16 reporting persons, likely in connection with the company's upcoming IPO.
Key Facts
- CEO Luca Santarelli holds 4,578,110 common shares and options to purchase 163,854 common shares at $0.02 per share, vesting over 36 months from April 30, 2026.
- CMO Omar Khwaja holds 642,136 common shares and options to purchase 318,830 common shares at $0.02 per share, vesting over 36 months from April 30, 2026.
- Director Otello Stampacchia reports indirect beneficial ownership of 3,590,530 common shares (on an as-converted basis) through Omega Fund VII, L.P. and Omega Fund VIII, L.P., including Series A and Series B preferred shares convertible 1:1 into common shares.
- Director Sandip Kapadia reports no securities beneficially owned.
- All four filings include a power of attorney authorizing Scott Applebaum, Diego Ramos, and Claudia D'Augusta to execute Section 16 filings on their behalf.
Financial Impact
Insider holdings disclosed; no transaction or monetary value stated beyond option exercise price of $0.02 per share.
Risk Factors
- No financial data or guidance provided; pre-revenue biotech with no disclosed product revenue or clinical trial results.
- Pre-IPO stage means high uncertainty on valuation and market reception.
Documents Analyzed
This report is based on 16 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (WWB), Batch item 1 | 0002162137-26-000003 |
| Document: 0002162137-26-000003-index-headers.html | 0001776393-26-000005 |
| Document: 0002162137-26-000003-index.html | 0001361712-26-000007 |
| Document: 0002162137-26-000003.txt | 0001677141-26-000009 |
| 3 Filing (WWB), Batch item 5 | 0001776393-26-000005 |
| Document: 0001776393-26-000005-index-headers.html | 0002162137-26-000003 |
| Document: 0001776393-26-000005-index.html | 0002162137-26-000003 |
| Document: 0001776393-26-000005.txt | 0002162137-26-000003 |
| 3 Filing (WWB), Batch item 9 | 0001361712-26-000007 |
| Document: 0001361712-26-000007-index-headers.html | 0002162137-26-000003 |
| Document: 0001361712-26-000007-index.html | 0002162137-26-000003 |
| Document: 0001361712-26-000007.txt | 0002162137-26-000003 |
| 3 Filing (WWB), Batch item 13 | 0001677141-26-000009 |
| Document: 0001677141-26-000009-index-headers.html | 0002162137-26-000003 |
| Document: 0001677141-26-000009-index.html | 0002162137-26-000003 |
| Document: 0001677141-26-000009.txt | 0002162137-26-000003 |
Track record
15 reports on WWB
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $30.04 Now $30.04 +0.00% settles Dec 16
- Nov 13, 20263d ago Press Release Bullish 5/10 Entry $18.35 Now $30.04 +63.71% settles Dec 15
- Nov 13, 20263d ago EFFECT Neutral 6/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 3/10 Viewing Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers